-
Changes in drug-related insurance in the past three years: low prices, selling points and perceptions
Time of Update: 2021-09-29
Data source: Latitude Health databaseFrom the perspective of the top ten medicines, mainly high-priced drugs newly included in the medical insurance catalogue, which can effectively control risks.
-
19 provinces opened the curtain on the centralized procurement of Chinese patent medicines, and how would it affect?
Time of Update: 2021-09-29
On September 25, the Hubei Province Pharmaceutical Price and Bidding Purchasing Management Service Network issued the "Announcement of the Centralized Procurement of Proprietary Chinese Patent Medicines (No.
-
With the vigorous development of my country's pharmaceutical industry, the importance of pharmaceutical packaging equipment will increase day by day
Time of Update: 2021-09-29
The analysis believes that with the development of the pharmaceutical packaging market and the continuous investment of pharmaceutical companies, the intelligent and green pharmaceutical packaging equipment in the future may become the main trend of the development of the industry .
-
Sales expenses fell for the first time in 5 years, and pharmaceutical companies began to attach importance to R&D investment
Time of Update: 2021-09-29
According to the data, among the 384 listed companies in the pharmaceutical industry classified by CITIC, 73 listed companies invested more than 100 million yuan in research and development in the first half of the year, compared with 53 in the same period last year.
-
Hyundai Pharmaceutical Holding Subsidiary Receives Marketing License for Relycoxib Tablets
Time of Update: 2021-09-29
On September 23, Hyundai Pharmaceutical issued an announcement stating that its controlling subsidiary Sinopharm Zhijun received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, and agreed to rely on the marketing license of coxib tablets (30mg, 60mg).
-
INOVIO authorized to conduct vaccine candidate trials in Mexico
Time of Update: 2021-09-29
The company recently received regulatory authorization to conduct trials in Brazil and the Philippines INOVIO and partner Ai Di Weixin are collaborating in a global phase 3 trial in regions with insuf
-
Peking University Medicine's antipyretic, analgesic and anti-inflammatory drug Celecoxib Capsules obtained "Drug Registration Certificate"
Time of Update: 2021-09-29
On September 23, Peking University Pharmaceutical issued an announcement stating that the company's product Celecoxib capsules had recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration .
-
As the domestic ADC drug market continues to develop, competition is increasing
Time of Update: 2021-09-29
The announcement showed that SHR-A1904 for injection is an antibody-drug conjugate targeting tumor-specific antigens.
In recent years, with the continuous maturity of ADC drug research and development technology, this market has gradually become hot, and it is attracting more and more companies to enter this field .
-
Novavax announces results of phase 3 clinical trial of influenza vaccine
Time of Update: 2021-09-29
(Nasdaq: NVAX), a biotechnology company dedicated to the development and commercialization of next-generation vaccines for severe infectious diseases The journal “Lancet ID” published the complete results of the key Phase 3 clinical trial of NanoFlu™, which is the company’s recombinant quadrivalent seasonal influenza vaccine candidate using Matrix-M™ adjuvant .
-
Centralized procurement of Chinese patent medicines is frequent, how should relevant companies respond?
Time of Update: 2021-09-29
Recently, the Hubei Province Pharmaceutical Price and Bidding Purchasing Management Service Network issued the "Announcement on Centralized Procurement of Proprietary Chinese Medicines by the Inter-provincial Alliance of Chinese Patent Medicines .
-
Obtained FDA Fast Track Qualification!
Time of Update: 2021-09-29
Prior to this, APG-115 has obtained five orphan drug qualifications (ODD) granted by the FDA, one of which is indicated for stage IIB-IV melanoma .
About Yasheng PharmaceuticalAbout Yasheng PharmaceuticalAscent Pharmaceuticals is an original innovative drug research and development company based in China and facing the world in the clinical development stage.
-
Under the collection!
Time of Update: 2021-09-29
Who knows that starting from 2020, the state has implemented centralized bidding for products that are currently in large quantities in hospitals and commonly used by the people, and the policy of mass procurement has greatly reduced the number of drugs.
-
No entry: Neurology clinic refuses to use Aduhelm, a new drug for Alzheimer's disease
Time of Update: 2021-09-29
According to a note on its website, considering the high price of Aduhelm-the average annual treatment cost per patient is $56,000-and the ambiguous clinical benefits, doctors at the Neurology Center have agreed to refuse to use it until the dispute is clarified.
-
How to take the path of high-quality development of the pharmaceutical industry?
Time of Update: 2021-09-29
Compared with the traditional model, by embracing digitalization, pharmaceutical companies can greatly improve production efficiency, effectively reduce labor costs, and ensure drug safety, adding new impetus to the development of the entire pharmaceutical industry .
-
Frontier Bio-Akening obtained the "Drug Registration Certificate" approved and issued by Cambodia
Time of Update: 2021-09-29
On September 23, Frontier Bio announced that the company’s core product, Aikening, had recently received the "Drug Registration Certificate" approved and issued by the Ministry of Health of Cambodia .
-
Lihui Zou, Vice President of Fosun Pharma resigns
Time of Update: 2021-09-29
Lihui Zou .
Lihui Zou applied to the company's board of directors to resign from the position of vice president due to personal reasons .
Lihui Zou will no longer serve as the vice president of the company from September 22, 2021 .
-
Eli Lilly’s application for new indications for IL-17A inhibitors is accepted by CDE
Time of Update: 2021-09-29
At present, the drug has been approved by the FDA to treat a variety of diseases, including moderate to severe plaque psoriasis, active psoriatic arthritis (PsA) in adult patients, ankylosing spondylitis, and active inflammation with objective symptoms non-radiological for axial spondyloarthritis (nr-axSpA) patients, and so on .
-
Hunan Provincial Food and Drug Administration: "Practicing Pharmacist Registration Certificate" was invalidated by 77 personnel
Time of Update: 2021-09-29
The registration certificates of 77 licensed pharmacists in one province were revoked according to law, and the certificates were cancelled and invalidated . 77 licensed pharmacists whose registratio
-
Olin Biosorbent Tetanus Vaccine Obtained Drug Re-registration Approval Notice
Time of Update: 2021-09-29
Upon review, the company declared that the adsorbed tetanus vaccine complied with the "Administrative Measures for Drug Registration" 》, agree to re-register .
The company obtained the first registration approval for tetanus vaccine drug in October 2016.
-
my country's API industry needs to take precautions to prevent overcapacity
Time of Update: 2021-09-29
However, analysts pointed out that while China's API companies attach importance to the international market, they should also take into account the domestic market .
